Over-Expression of GUSB Leads to Primary Resistance of Anti-PD1 Therapy in Hepatocellular Carcinoma

Over-Expression of GUSB Leads to Primary Resistance of Anti-PD1 Therapy in Hepatocellular Carcinoma

Immunotherapy treatments, particularly immune checkpoint blockade, can result in benefits in clinical settings. But many pre-clinical and clinical studies have shown that resistance to anti-PD1 therapy frequently occurs, leading to tumor recurrence and treatment failure, including in patients with h...

Full description

Bibliographic Details
Main Authors: Xiangyi Kong, Zhiying Zheng, Guoxin Song, Zihao Zhang, Hanyuan Liu, Junwei Kang, Guoqiang Sun, Guangshun Sun, Tian Huang, Xiao Li, Dawei Rong, Ke Wang, Weiwei Tang, Yongxiang Xia
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Immunology
Subjects:
289 nanostring panel RNA sequencing
GUSB
PD-1
primary resistance
hepatocellular carcinoma
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.876048/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.876048/full

Similar Items